Similarly, the RET inhibitor pralsetinib demonstrated a 53% ORR across RET-fusion-positive non-NSCLC/non-thyroid tumors, with particularly promising results in pancreatic cancer (3/3 responders) and cholangiocarcinoma (2/3 responders) [130]. This evidence concerns the gene RET and familial pancreatic carcinoma.